FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver